Differences in generalist and specialist physicians’ knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
To quantify the extent and determinants of underutilization of angiotensin-converting enzyme (ACE) inhibitors for patients with congestive heart failure, especially with respect to physician specialty and clinical indication.
Survey of a national systematic sample of physicians.
Five hundred family practitioners, 500 general internists, and 500 cardiologists.
Measurements and main results
Physicians’ choice of medications were determined for four hypothetical patients with left ventricular systolic dysfunction: (1) new-onset, symptomatic; (2) asymptomatic; (3) chronic heart failure, on digitalis and diuretic; and (4) asymptomatic, post-myocardial infarction. For each patient, randomized controlled trials have demonstrated that ACE inhibitors decrease mortality or the progression of symptoms. Among the 727 eligible physicians returning surveys (adjusted response rate 58%), approximately 90% used ACE inhibitors for patients with chronic heart failure who were already taking digitalis and a diuretic. However, family practitioners and general internists chose ACE inhibitors less frequently (p≤.01) than cardiologists for the other indications. Respective rates of ACE inhibitor use for each simulated patient were new-onset, symptomatic (family practitioners 72%, general internists 76%, cardiologists 86%); asymptomatic (family practitioners 68%, general internists 78%, cardiologists 93%); and asymptomatic, post-myocardial infarction (family practitioners 58%, general internists 70%, cardiologists 94%). Compared with generalists, cardiologists were more likely (p≤.05) to increase ACE inhibitors to a target dosage (45% vs 26%) and to tolerate systolic blood pressures of 90 mm Hg or less (43% vs 15%).
Compared with cardiologists, family practitioners and general internists probably underutilize ACE inhibitors, particularly among patients with decreased ejection fraction who are either asymptomatic or post-myocardial infarction. Educational efforts should focus on these indications and emphasize the dosages demonstrated to lower mortality and morbidity in the trials.
- Franks P, Nutting PA, Clancy CM. Health care reform, primary care, and the need for research. JAMA. 1993;270:1449–53. CrossRef
- Kassirer JP. Access to specialty care. N Engl J Med. 1994;331: 1151–3. CrossRef
- Stevenson WG, Stevenson L, Middlekauff HR, et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol. 1995;26:1417–23. CrossRef
- Garg R, Yusuf S, Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450–6. CrossRef
- The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302. CrossRef
- The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685–91. CrossRef
- Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–77. CrossRef
- Konstam M, Dracup K, Baker D, et al. Heart Failure: Evaluation and Care of Patients with Left-Ventricular Systolic Dysfunction. Clinical Practice Guideline No. 11. Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services; June 1994. AHCPR publication no. 94-0612.
- American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol. 1995;26:1376–98. CrossRef
- Young JB, Weiner DH, Yusuf S, et al. Patterns of medication use in patients with heart failure: a report from the Registry of Studies of Left Ventricular Dysfunction (SOLVD). South Med J. 1995; 88:514–23.
- Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 1993;22(suppl A):14–9A.
- McDermott MM, Feinglass J, Sy J, Gheorghiade M. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. Am J Med. 1995;99:629–35. CrossRef
- Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health. 1997;87:643–8. CrossRef
- Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J. 1994;71:584–7. CrossRef
- Rajfer SI. Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol. 1993; 22(suppl A):198–200A.
- Chin MH, Wang JC, Žhang JX, Lang RM. Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure: effect of physician specialty and patient characteristics. J Gen Intern Med. 1997;12:563–6. CrossRef
- Aday LA. Designing and Conducting Health Surveys. San Francisco, Calif: Jossey-Bass Publishers; 1989:121–4.
- Stross JK, Harlan WR. The dissemination of new medical information. JAMA. 1979;241:2622–4. CrossRef
- Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol. 1996;28:1323–7. CrossRef
- Massie BM, Kramer BL, Topic N. Lack of relationship between short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation. 1984;69:1135–41.
- Swedberg K, Eneroth P, Kjekshus J, Snapinn S, and the CONSENSUS Trial Study Group. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS Trial). Am J Cardiol. 1990;66:40–5D. CrossRef
- Jones TV, Gerrity MS, Earp J. Written case simulations: do they predict physicians' behavior? J Clin Epidemiol. 1990;43:805–15. CrossRef
- Ayanian JŽ, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNeil BJ. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 1994;331:1136–42. CrossRef
- Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med. 1996;124:414–21.
- Hlatky MA, Fleg JL, Hinton PC, et al. Physician practice in the management of congestive heart failure. J Am Coll Cardiol. 1986; 8:966–70. CrossRef
- Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Milbank Q. 1989;67:268–317. CrossRef
- Leape LL. Practice guidelines and standards: an overview. Qual Rev Bull. 1990;16:42–9.
- Hillman AL, Pauly MV, Kerman K, Martinek CR. HMO managers' views on financial incentives and quality. Health Affairs. 1991; 10:207–219. CrossRef
- Kerr EA, Mittman BS, Hays RD, Siu AL, Leake B, Brook RH. Managed care and capitation in California: how do physicians at financial risk control their own utilization? Ann Intern Med. 1995;123:500–4.
- Greco PJ, Eisenberg JM. Changing physicians' practices. N Engl J Med. 1993;329:1271–3. CrossRef
- Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the read-mission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190–5. CrossRef
- West JA, Miller NH, Parker KM, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol. 1997;79:58–63. CrossRef
- Health Care Financing Review, Statistical Supplement, Baltimore, Md: U.S. Department of Health and Human Services: 1995:56.
- Differences in generalist and specialist physicians’ knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure
Journal of General Internal Medicine
Volume 12, Issue 9 , pp 523-530
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- angiotensin-converting enzyme (ACE) inhibitor
- congestive heart failure
- physician behavior
- quality of care
- Industry Sectors
- Author Affiliations
- 1. Section of General Internal Medicine, Department of Medicine, University of Chicago (Ill.) Medical Center, 5841 S. Maryland Ave., MC 6098, 60637, Chicago, IL
- 3. Section of Cardiology, Department of Medicine, University of Chicago (Ill.) Medical Center, 5841 S. Maryland Ave., MC 6098, 60637, Chicago, IL